Spyre Therapeutics CFO exercises options, sells shares
Spyre Therapeutics, Inc. CFO Scott L. Burrows reported an option exercise-and-sale sequence on August 3, 2026.
Rhea-AI Filing Summary
Spyre Therapeutics, Inc. CFO Scott L. Burrows reported an option exercise-and-sale sequence on August 3, 2026. He exercised stock options for 7,500 shares of common stock at an exercise price of $14.50 per share, then sold 7,500 shares in three transactions at weighted average prices of $95.21, $96.30 and $97.10, all pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. Following the transactions, he continues to hold options covering 344,857 shares that expire on September 1, 2033 and 67,476 restricted stock units vesting in two equal installments on September 1, 2026 and 2027, subject to continued employment.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 7,500 shares ($608K approx. pre-tax spread)
Exercise and Sale
5 txns
Insider
Burrows Scott L
Role
Chief Financial Officer
Sold
7,500 shs ($717K)
Approx. gross sale proceeds
$717K
Approx. exercise cost
$109K
Approx. pre-tax spread
$608K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F1, F5 | 7,500 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 7,500 | $14.50 | $109K |
| Sale | Common Stock F1, F2 | 5,100 | $95.21 | $486K |
| Sale | Common Stock F1, F3 | 2,300 | $96.30 | $221K |
| Sale | Common Stock F1, F4 | 100 | $97.10 | $10K |
Holdings After Transaction:
Stock Option (Right to Buy) — 344,857 contracts (Direct);
Common Stock — 97,994 shares (Direct)
Footnotes (5)
- F1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025.
- F2. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $94.84 to $95.83, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
- F3. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $95.85 to $96.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F4. Includes 67,476 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting, one share of Common Stock. The RSUs vest in two equal installments on each of September 1, 2026 and 2027, subject to the Reporting Person's continued employment with the Issuer.
- F5. This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.
Key Figures
Options exercised: 7,500 shares
Exercise price: $14.50 per share
Shares sold at $95.21: 5,100 shares
+4 more
7 metrics
Options exercised
7,500 shares
Stock options exercised into common stock on August 3, 2026
Exercise price
$14.50 per share
Exercise price of stock option converted into common stock
Shares sold at $95.21
5,100 shares
Weighted average sale price $95.21; individual trades between $94.84 and $95.83
Shares sold at $96.30
2,300 shares
Weighted average sale price $96.30; individual trades between $95.85 and $96.82
Shares sold at $97.10
100 shares
Additional common shares sold at $97.10 per share
Options remaining
344,857 shares
Option shares underlying the award following the reported exercise
Restricted stock units
67,476 RSUs
RSUs vesting in two equal installments on September 1, 2026 and 2027
Key Terms
Rule 10b5-1 trading plan, restricted stock units, weighted average price, reverse stock split
4 terms
Rule 10b5-1 trading plan financial
"This transaction was executed pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
restricted stock units financial
"Includes 67,476 restricted stock units (RSUs). Each RSU represents a contingent right"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
weighted average price financial
"The price reported above is a weighted average price. The shares were sold in multiple transactions"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
reverse stock split financial
"adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023"
A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Spyre Therapeutics (SYRE) CFO Scott Burrows report?
Scott Burrows reported an exercise-and-sale sequence involving 7,500 shares. He exercised stock options at $14.50 per share on August 3, 2026, receiving common stock and then selling the same 7,500 shares in three trades at weighted average prices of $95.21, $96.30 and $97.10.
Were the SYRE insider transactions made under a Rule 10b5-1 trading plan?
Yes. A footnote states the transactions were executed under a Rule 10b5-1 trading plan adopted on November 10, 2025. This indicates the timing and amounts were pre-arranged, rather than discretionary trades based on contemporaneous market information.
What Spyre Therapeutics (SYRE) equity awards does the CFO continue to hold after these trades?
After the reported transactions, the CFO continues to hold options covering 344,857 shares of common stock expiring on September 1, 2033, as well as 67,476 restricted stock units that each convert into one share upon vesting, subject to continued employment.
When do the SYRE restricted stock units held by the CFO vest?
The 67,476 restricted stock units held by the CFO vest in two equal installments on September 1, 2026 and September 1, 2027. Each RSU represents a contingent right to receive one share of Spyre Therapeutics common stock upon vesting, subject to continued employment.
What are the key terms of the Spyre Therapeutics (SYRE) options exercised by the CFO?
The exercised option had an exercise price of $14.50 per share and expires on September 1, 2033. It originally covered 404,857 shares, with one quarter vesting on September 1, 2024 and the remainder vesting monthly over three years, subject to continued employment.
AI-generated analysis. How Rhea-AI works. Not financial advice.
